- Who We Are
- What We Do
- How To Help
- Contact Us
Albert Einstein College of Medicine
Targeting NOXA methylation to overcome Bortezomib resistance in MCL
Mantle cell lymphoma is an aggressive type of non-Hodgkin’s lymphoma characterized by frequent relapses and usually fatal in the majority of patients. We are trying to understand precisely why patients do not respond to Bortezomib, a standard chemotherapy for this disease using cutting-edge next generation sequencing tools. We will then find ways to make cancer cells more sensitive to Bortezomib by switching on our body’s internal cell death mechanisms. Our studies are aimed at ultimately developing clinical trials that will overcome Bortezomib resistance in MCL patients.